With one new drug on the market in the US and two more pending at the US Food and Drug Administration, 2020 is positioned to be a turning point for the treatment of sickle cell disease. Patients with the devastating blood disorder, which results in acute pain crises, long-term organ damage and a shortened lifespan, have had few treatment options, but the outlook for sickle cell R&D is brighter than it has been.
"The time has come. We are at the cusp of improving the quality of life for people with sickle cell...